Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Jun 21, 2014; 20(23): 7356-7365
Published online Jun 21, 2014. doi: 10.3748/wjg.v20.i23.7356
Published online Jun 21, 2014. doi: 10.3748/wjg.v20.i23.7356
Figure 1 The pathogenesis of non-alcoholic fatty liver disease and the possible effect of incretin system components in treatment.
Modified according to Dowman et al[63]. ACC: Acetyl-CoA carboxylase; DPP-4: Dipeptydil peptidase-4; GLP-1: Glucagon-like peptide-1; FFA: Free fatty acid; FAS: Fatty acid synthetase; SREPB1c: Sterol regulatory element-binding protein.
- Citation: Blaslov K, Bulum T, Zibar K, Duvnjak L. Incretin based therapies: A novel treatment approach for non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(23): 7356-7365
- URL: https://www.wjgnet.com/1007-9327/full/v20/i23/7356.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i23.7356